TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases

TRIMTECH Therapeutics raises $31M to enhance its TRIMTAC platform, targeting protein aggregates in neurodegenerative diseases for improved therapeutic outcomes.